English (United States)
English (Canada)
English (Other Regions)
French
German
Italian
Japanese
Russian
Spanish
Chinese
VASCADE MVP® System
Make a selection to learn more
VASCADE MVP® System
Make a selection to learn more
3.9 hour reduction in median time to ambulation
Ordering Information | AMBULATE Trial | Clinical Data
The AMBULATE clinical study has shown that the use of VASCADE MVP® system reduces the time to ambulation. It was demonstrated that the median time to ambulation was 2.2 hours, which results in a 64% reduction in median time to ambulation compared to manual compression.1
Designed for EP Procedures
Ordering Information | AMBULATE Trial
The VASCADE MVP® system is FDA approved for enabling same day discharge in patients who have undergone catheter-based cardiac arrhythmia ablation procedures utilizing 6-12F inner diameter (15F maximum outer diameter) procedural sheaths, with single or multiple access sites in one or both limbs6 and is the only extravascular closure device to offer collagen with a dual method of action, mechanical and physiological.9 Using a single operator, the VASCADE MVP system is simple and easy to use and leaves no sutures or other materials left behind in the vessel. The resorbable thrombogenic plug expands by 13X to fill the tissue tract.† The VASCADE MVP system allows for re-access, after 30 days, for repeat ablation procedures.
.jpg%3Fh%3D429%26iar%3D0%26w%3D429&w=3840&q=75)
Proven by EPs
Ordering Information | AMBULATE Trial
VASCADE MVP® venous vascular closure system has been proven in the prospective, multicenter randomized AMBULATE Clinical Trial,1 demonstrating a 3.9 hour (64%) reduction in median time to ambulation as well a 63% improvement in patient satisfaction and a 58% reduction in opioid use post ablation, when compared to manual compression. The VASCADE MVP system has also demonstrated same day discharge success in the prospective multicenter AMBULATE Same Day Discharge Clinical Studies,4, 5 where 91.2% of patients were sent home the same day using the VASCADE MVP system.4,5 In addition, 99.7% of VASCADE MVP same day discharge patients had no intervention during follow up7 and there were zero (0%) major complications.8
.jpg%3Fh%3D429%26iar%3D0%26w%3D429&w=3840&q=75)
Simple and Easy to Use
✓ Single operator
✓ Indicated
• For use in 6F to 12F ID (max 15F OD) 12 cm introducer sheathsa
• For single or multiple access sites in one or both limbs
✓ 2 mechanisms of action
• Mechanical
• Physiological
✓ Extravascular design
• No permanent or intraluminal implants
• No sutures or material left in vessel
✓ Bioabsorbable and thrombogenic collagen patch
• Expands to fill tissue tract
aOverall length of the sheath (including the hub) needs to be less than 15 cm
.jpg%3Fh%3D360%26iar%3D0%26w%3D360&w=3840&q=75)
Resource Centre
Find the information you need as you browse through helpful, on-demand information to aid in your understanding of our vascular closure solutions.
Featured Resources View all resources
Instructions for Use
The VASCADE MVP® Venous Vascular Closure System is intended to seal the femoral vein access site(s) by delivering a resorbable Collagen Patch, extra-vascularly, at the venotomy site to aid in achieving hemostasis.
VASCADE MVP® Brochure
Our VASCADE MVP system provides rapid hemostasis for electrophysiology procedures, eliminating the need for manual compression and enabling patients to get up and moving earlier.
AMBULATE Trial
This prospective, multicenter, randomized study compared the efficacy and safety of VASCADE MVP® to manual compression for closing multiple access sites after catheter-based EP procedures.
AMBULATE Same Day Discharge Clinical Studies
This prospective, multicenter single arm registry evaluates procedural outcomes using VASCADE MVP® following atrial fibrillation interventions for patients who are discharged the same day.
Ordering Information
To place an order please contact Customer Service.
1. Natale A, et al. Venous vascular closure system versus manual compression following multiple access electrophysiology procedures: The AMBULATE Trial. JACC Clin Electrophysiol 2020; 6(1):111-124.
2. Al-Ahmad A, et al. Results from the prospective, multicenter AMBULATE-CAP trial: Reduced use of urinary catheters and protamine with hemostasis via the mid-bore venous vascular closure system. VASCADE MVP following multi-access cardiac ablation procedures. J Cardiovasc Electrophysiol 2021. 32(2): 191-99.
3. AMBULATE Same Day Discharge Registry Retrospective Study: NCT04538781.
4/5. Eldadah ZA, et al. Same-day discharge following catheter ablation and venous closure with VASCADE MVP: A post-market registry. J Cardiovasc Electrophysiol 2022. https://doi. org/10.1111/jce.15763. NCT04203329.
6. Catheter-based cardiac ablations requiring two or more venous access sites within the same limb. See VASCADE MVP IFU 5686 Indications for Use.
7. Data on file at Haemonetics.
8. Major venous access site closure-related complications through the follow up.
COL-COPY-002256-US(AD)
Connect with us
Not all products are available in all markets.